Sangamo Therapeutics, Inc (SGMOQ) stock
Close on Oct 19, 2026Market cap $39.43MP/E –Yield –
Sangamo Therapeutics, Inc saw revenue fall 45.8% to $34.56M over the twelve months to Mar 31, 2026. Free cash flow was -$90.46M. At the latest close the market valued the company at $39.43M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Mar 31, 2026
Valuation
- Market cap
- $39.43M
- P/E ratio
- –
- Price to sales
- 1.14
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -229.41%
Fundamentals
- Revenue
- $34.56M
- Net income
- -$123.33M
- EPS, diluted
- -$0.38
- Free cash flow
- -$90.46M
- Book value per share
- -$0.05
- Diluted shares
- 390M
Trading
- Previous close
- $0.11
- Open
- $0.07
- Day's range
- $0.07 – $0.14
- Volume
- 1,896,966
- Average volume (20 days)
- 1,865,087
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | SGMOQ | S&P 500 | Difference | SGMOQ per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -30.2% | +0.6% | −30.8 pts | ||
| 3 months | +55.7% | +3.4% | +52.3 pts | ||
| Year to date | -75.9% | +13.3% | −89.2 pts | ||
| 1 year | -84.2% | +16.6% | −100.8 pts | ||
| 3 years | -80.9% | +86.4% | −167.3 pts | -42.4% | +23.1% |
| 5 years | -98.8% | +81.9% | −180.7 pts | -58.8% | +12.7% |
| 10 years | -97.2% | +318.9% | −416.0 pts | -30.0% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Sangamo Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- News
About Sangamo Therapeutics
Biological Products, (No Diagnostic Substances)
Sangamo Therapeutics, Inc. is a biotechnology company that researches and develops genomic medicines and gene therapy product candidates. The company focuses on developing therapies utilizing its zinc finger technology platform, zinc finger transcriptional regulators, and capsid delivery technologies. Its clinical-stage and core preclinical programs include development candidates for rare genetic conditions and neurological indications, such as isaralgagene civaparvovec for Fabry disease and a hemophilia A program. Sangamo targets patients with genetic and neurodevelopmental conditions and works directly with major pharmaceutical and biotechnology partners, licensing its technology assets and collaborating on clinical development.
Company profile, executives and historySangamo Therapeutics stock: common questions
What is Sangamo Therapeutics's stock price?
SGMOQ closed at $0.10 on Oct 19, 2026, down 8.17% on the day.
What is Sangamo Therapeutics's market cap?
Sangamo Therapeutics was worth $39.43M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is SGMOQ's P/E ratio?
Sangamo Therapeutics lost money over the twelve months to Mar 31, 2026 (diluted EPS -$0.38), so it has no meaningful P/E ratio.
How much revenue does Sangamo Therapeutics make?
Sangamo Therapeutics reported revenue of $34.56M for the twelve months to Mar 31, 2026, down 45.8% from a year earlier.
Does Sangamo Therapeutics pay a dividend?
No. Sangamo Therapeutics has not paid a cash dividend over the last twelve months.
How has SGMOQ stock performed over the past year?
Including dividends, SGMOQ returned -84.2% over the past year, against +16.6% for the S&P 500.
Who are Sangamo Therapeutics's competitors?
Companies most similar to Sangamo Therapeutics by business, industry and size include MGX, EDIT, VYGR, FDMT, CRSP.
See a number that looks wrong?